Bundibugyo Ebola: Inside the race to develop vaccines and treatments
Global health authorities are racing to identify medical options to help contain an Ebola outbreak in eastern Democratic Republic of Congo, linked to the Bundibugyo strain of the virus.
Unlike for the more common Zaire strain, there are no approved vaccines or treatments for Bundibugyo.
The latest outbreak is suspected to have led to about 906 cases in the Democratic Republic of Congo, including 223 suspected deaths, with the World Health Organization warning that the toll is likely to rise. Bundibugyo ebolavirus, or BDBV, has a fatality rate of up to 40%.
A small number of experimental vaccines and therapies are being assessed, and global health authorities are examining whether any existing Ebola treatments might offer protection — so far supported only by limited animal data.
Most experimental treatments have not yet been tested in humans and would require emergency or compassionate-use authorization before they are deployed in Congo.
The WHO on Thursday recommended prioritizing several experimental drugs, including antibodies, antivirals and vaccines, for the treatment and prevention of BDBV.
Here is what we know of these candidates so far:
VACCINES
- A Bundibugyo-specific vaccine, which uses the same technology as Merck’s approved vaccine Ervebo for the Zaire strain, has shown survival benefit in non-human primates in a 2023 proof-of-concept study.A spokesperson for the University of Texas Medical Branch, whose researchers were involved in the study, said discussions are underway to advance the vaccine, but nothing has been finalized. The WHO has indicated a potential six-to-nine-month timeline to manufacture an rVSV Bundibugyo vaccine.
- The WHO said on Thursday a single-dose rVSV Bundibugyo vaccine being developed by the International AIDS Vaccine Initiative is the most promising candidate to prevent BDBV.The agency said development of the single-dose vaccine would likely take seven to nine months before it is ready for assessment in a clinical trial.
- The WHO has recommended prioritizing another vaccine candidate, ChAdOx1 Bundibugyo, being developed by Oxford University and the Serum Institute of India.The potential vaccine is based on ChAdOx1 technology, which was used in the Oxford/AstraZeneca COVID-19 vaccine, and is being manufactured by the Serum Institute.The company started production under its “emergency response framework,” alongside partners Coalition for Epidemic Preparedness Innovations, or CEPI, and the University of Oxford, as soon as it got word of the outbreak this month, a spokesperson said.Doses could be ready within two to three months for efficacy assessment through a clinical trial, the WHO said, adding that additional animal studies have yet to be conducted.
The WHO said experts considered a single dose of the vaccine candidate potentially suitable for contacts of Ebola cases, while a two-dose regimen might be used for high-risk but unexposed groups, including healthcare workers and frontline responders.
The Oxford Vaccine Group said it is working to generate pre-clinical data to support the development and testing of the ChAdOx1 BDBV vaccine.
CEPI, which funded some of the early COVID-19 vaccines and aims to have shots available within 100 days of an outbreak, said it is in talks with both candidates about how to speed up development.
ANTIBODY-BASED THERAPIES
- The WHO has recommended prioritizing privately held Mapp Biopharmaceutical’s pan-ebolavirus antibody drug, MBP134 — a combination of two human monoclonal antibodies — for clinical trials among confirmed BDBV cases.Initially studied for the Sudan ebolavirus strain, the drug was found to be safe and well tolerated in early-stage trials. Development has been backed by the US Biomedical Advanced Research and Development Authority, or BARDA.BARDA said it is coordinating shipments of the investigational treatment for potential use in high-risk Americans exposed to the virus.Mapp said MBP134 has shown similar activity against all known ebolaviruses and that it is working with the WHO and other authorities as part of the response to the Congo outbreak.
- Regeneron Pharmaceuticals’ antibody drug candidate, maftivimab, is also being explored as a potential treatment by the WHO. According to the company, it has been shown in a lab to be active against the Bundibugyo Ebolavirus.Regeneron said it is working to prepare existing supply of maftivimab for use in upcoming clinical trials.The FDA has approved a combination of maftivimab and two other antibodies, atoltivimab and odesivimab, under the brand name Inmazeb, to treat Zaire Ebolavirus infection in adult and pediatric patients.The company said it recently donated 500 doses of Inmazeb to the WHO, which could be used if found helpful.
“Supply of Inmazeb is already on the ground in the DRC, should WHO wish to utilize it for immediate treatment or as an additional component of the study,” Regeneron said.
- Human monoclonal antibodies isolated from Bundibugyo survivors have also been explored as potential treatments.One candidate, BDBV289-N, demonstrated efficacy in a 2018 animal study. The study, conducted by a group of researchers with support from the US National Institutes of Health, showed the antibody gave up to 100% protection in infected monkeys, even when treatment started up to eight days after the infection.
ANTIVIRAL DRUGS
Gilead Sciences’ experimental oral antiviral drug obeldesivir is being considered as a potential post-exposure treatment by the WHO to prevent those exposed to Ebola from developing the disease.
Once-daily obeldesivir given for 10 days provided up to 100% protection in monkeys against the Zaire and Sudan Ebola strains when treatment began 24 hours after exposure.
“Obeldesivir is predicted to be active against this particular (Bundibugyo) strain. While not approved for this, we do have preclinical data that shows positive results,” a company spokesperson said.
Gilead’s antiviral remdesivir has shown activity against the Bundibugyo virus in laboratory studies conducted by researchers at the University of Texas Medical Branch. Some data suggest the drug, given as an intravenous infusion, may have stronger activity against BDBV than against the Zaire Ebola strain.
The WHO has also recommended a combination therapy using a monoclonal antibody and remdesivir for evaluation.
DIAGNOSTIC TESTS
The WHO had indicated that limited testing capacity for the Bundibugyo strain was slowing response to the outbreak. Here are tests that can detect the infection.
- BioFire Defense, an affiliate of French diagnostic firm bioMérieux, makes an FDA-cleared test – BioFire Global Fever Special Pathogens Panel – that can detect multiple Ebola species, including Bundibugyo.A company spokesperson said it is increasing production capacity and engaging with public health stakeholders and international contacts to assess potential needs.
- Germany-based firm Altona Diagnostics’ test, called RealStar Filovirus Screen RT-PCR Kit 1.0, is being used to detect the Bundibugyo outbreak in Congo. The firm has ramped up production to support local testing facilities in Congo.
Shows
See AllAM Live
AM Live is NTV's morning current affairs show that sets the agenda for the day with insightful panels every weekday.
Business Redefined
Business Redefined is Kenya’s premier thought leadership platform for unpacking matters regarding economic and finance policy as well demystifying complex developments in the region’s capital markets.
Comedies
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Creatives & Coins Podcast
A podcast that dives deep into the vibrant and rapidly evolving digital creative economy in Kenya. This show explores the lives, challenges, and triumphs of individuals who are successfully navigating the gig and creative economies. From digital artists and content creators to freelance writers and tech entrepreneurs, we spotlight the voices that are shaping the future of work in Kenya.
Documentaries
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Entertainment
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Fixing The Nation
Fixing the Nation is a bold and groundbreaking show that will take an unflinching look at challenges facing the Kenyan society and the solutions that can move us forward. It is anchored by respected journalists Eric Lattif, Janet Mbugua, and Mariam Bishar. Podcast created by: Nation FM
Fixing the Nation
Fixing the Nation is a bold and groundbreaking show that will take an unflinching look at challenges facing the Kenyan society and the solutions that can move us forward. It is anchored by respected journalists Eric Lattif, Janet Mbugua, and Mariam Bishar
Full Episodes
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Gumzo La Sato
Gumzo La Sato is a live social issues show that aims to create awareness about issues affecting the larger society. The discussions range from Parenting, Marital bliss and struggles, Oppression, violence, and all matters of the Heart.
Health Diary
Health Diary is a weekly show that highlights different types of diseases/conditions and seeks ways to prevent, treat/manage them. The show debunks this through real life stories and also feature specialists in different fields, to offer medical advice on the same.
Letter To My Younger Self
Letter To My Younger Self is a podcast where guests get to write a letter to their younger self, from which Maxine formulates questions to ask them during the hour-long show.
Lunch N Rants
Take a minute outside your schedule to have a good laugh and conversations that resonate with you. Welcome to Lunch N Rant podcast where we talk about anything and everything life.
Nation Reports
Nation Reports is a weekly podcast offers an opportunity for listeners to interact with various reporters and journey with them as they unravel the biggest most emotive stories.
One Health Lens Podcast
Discussing health matters and human stories from Kenya and across Africa. We talk big picture from people to policy, ecosystems, and everything in between. Follow us on LinkedIn: https://www.linkedin.com/company/onehealthlens
Paradise Lost
Paradise Lost peeks through the story of Louis Otieno, the times, and everything in between.
Primetime
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Speaking of GEN Z
Speaking of Gen Z brings you entertaining but meaningful conversations about a generation that is trying to navigate through adulthood. Join hosts Michelle, Jackie and Esther as they unravel all things Gen Z.
Sport On
Sport-On is a 30-minute sports magazine show on NTV and 3 hours on NATION FM. The show seeks to give the sports “fanatics” and “funatics” comprehensive and in-depth coverage of sports both locally and internationally.
Tech-over
The extent of technological growth is beyond mere acknowledgment; it has seamlessly integrated into our daily existence. A few years ago, the notion of paying electricity bills through mobile money or recharging with 'tokens' in Kenya seemed inconceivable. Online product sales were considered distant, and artificial intelligence is rapidly reshaping various facets of our lives. Amidst these technological leaps, those with a solid understanding of tech can navigate challenges, seize opportunities, and build a sustainable livelihood. Tech over Show aims to be the platform facilitating discussions among thought leaders, innovators, tech companies, and the government, addressing challenges and opportunities in Kenya's thriving tech industry.
Thamani
Thamani is a business show which is dedicated to emerging issues regarding micro, small and medium size businesses.
The Politalk podcast
This is The Politalk podcast. Here we look into the ins and outs of everything Kenyan politics. We pull no punches and have no reason to sugarcoat anything that matters to Kenyans.
The Trend
A two-hour-long live show that airs on Fridays. The show focuses on what is current in the entertainment industry, controversial and popular across all media platforms targeting those aged between 25 and 35 years.
The trend podcast
The trend podcast highlights and captures the best of banter from #TTTT segment that airs every Friday on NTV. It's the TTTT EXTRA
The Wicked Edition
The Wicked Edition with Dr. King’ori seeks to address serious issues through humour and relatable wit. It is a two-part half hour show filmed in front of a live audience
Trending
A collection of our premium content. Diam curabitur vehicula A collection of our premium content. Diam curabitur vehicula
Twende
Twende is a travel show that highlights beautiful, unique, diverse locations, people, and cultures. The show offers fresh perspectives on familiar locations and memorable experiences in new ones.
Unscripted
This Saturday evening lifestyle show lets viewers share their stories and life experiences as openly & honestly for the purpose of shifting the culture of silence.
VIP Access
VIP ACCESS is Anyiko Owoko’s YouTube and podcast show on Music and Culture dedicated to promoting Africa’s most promising talent and creatives. This podcast grants you VIP access into timeless interviews while providing a platform for rising as well as established artists across the continent. Since launching in 2018, Anyiko has interviewed over 70 African music stars.
WADR
This weekly news show aims to have all sides of debate but not be constrained by it, listen to main voices in the contest but not allow them to hold the viewers hostage, entertain debate but allow push back with all due respect.
When death do us part
In this podcast, three widowers openly speak about the process of grief, how they found themselves exposed to the emotional turmoil of losing their wives, and how society still does not know how to deal with them.
Your World
Your World is a health, wellness and variety show. It provides a platform for audiences and experts to share their experiences on how to improve or manage health issues, across Kenya and the Africa region.